This is a review of the recent 3 year follow up of the CASTOR study – Daratumumab, bortezomib, and dexamethasone versus bortezomib and dexamethasone in patients with previously treated multiple myeloma.
The study involved almost 500 patients with a median follow up of 40 months. Commentary is provided by Professor Miles Prince, Professor of Medicine at both Melbourne and Monash Universities and Director of Cancer Immunology and Molecular Oncology at Epworth Healthcare.
Please login below to download this issue (PDF)